Results for the substance tezepelumab

Tezepelumab is a monoclonal antibody used for the treatment of severe asthma in patients who do not respond adequately to other therapies. It works by inhibiting thymic stromal lymphopoietin (TSLP), a protein involved in the inflammatory process associated with asthma.

The medication is administered via subcutaneous injection, usually once a month, as directed by a doctor. It is used as an adjunct therapy to reduce the frequency of asthma exacerbations.

Patients should be monitored for potential side effects, such as injection site reactions, respiratory infections, or headaches. It is important to inform the doctor of any unusual symptoms.

Common side effects include upper respiratory tract infections, headaches, and injection site reactions. In rare cases, severe allergic reactions or serious infections may occur. Patients should be informed of these risks before starting treatment.